The Diabetes Care Drugs Market is expected to register a CAGR of 9.4% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Diabetes Care Drugs Market report covers analysis by Product (Injectable, Oral Antidiabetic Drugs); Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Diabetes Care Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Diabetes Care Drugs Market Segmentation
Product- Injectable
- Oral Antidiabetic Drugs
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Strategic Insights
Diabetes Care Drugs Market Growth Drivers- Increasing Prevalence of Diabetes: Global diabetes cases are on the rise, especially Type 2 diabetes, which is a major driver for the diabetes care drugs market. The growth in diabetes prevalence is due to unhealthy diets, sedentary lifestyles, and an aging population. According to the World Health Organization, the prevalence of diabetes will reach over 500 million by 2030, hence increasing the demand for medications to regulate blood sugar.
- Advances in Drug Formulations and Therapies: Continuous development of innovative and effective drugs for diabetes has been the biggest influencer in terms of market growth. The most recent advancements in formulations of drugs include once-weekly injectable therapies, oral drugs with fewer side effects, and combination therapies that ensure better management of blood glucose levels and enhance patient adherence. Introductions of biologics and newer classes of drugs, such as GLP-1 receptor agonists and SGLT-2 inhibitors, are widening the range of therapeutic options available for diabetes care.
- Government Initiatives and Awareness Campaigns: Governments and health organizations around the world are stepping up efforts to control the rising diabetes epidemic through awareness campaigns, early diagnosis programs, and the promotion of lifestyle changes. This increased awareness is pushing demand for diabetes care drugs as more cases get diagnosed and require effective management. Public health programs, including free or subsidized diabetes care, are helping expand market access.
- Shift Towards Personalized Medicine: The approach of personalized medicine in the treatment of diabetes has become a major trend. Here, the approach to drug therapy has been highly focused on individualized patient profiles. Genetic and biomarker-based testing is increasingly being applied to determine the best drugs and optimal dosing levels. Personalized care approaches enhance treatment efficacy while reducing adverse effects, and therefore, contribute to the market growth of the specific drugs involved.
- Rising Biosimilars Trend in Diabetes Care: Biosimilars are the most impelling trend to enter the diabetes market. Biosimilars are more affordable versions of biologic drugs, which are gaining popularity as the patents to original biologics expire. The cost of managing diabetes is still a cause for concern in low- and middle-income economies; thus, biosimilars are helping to expand the reach in the market by increasing access to less expensive diabetes drugs.
- Integration of digital health technologies: Digital health tools, such as mobile apps, glucose monitoring devices, and telemedicine platforms, are increasingly integrated into diabetes care. These technologies help patients monitor their blood sugar levels, track medication adherence, and provide real-time data to healthcare providers. The use of digital tools to manage diabetes is improving outcomes and increasing patient engagement, creating a greater demand for diabetes medications that can be integrated with these technologies.
- Development of New Drug Classes: The development of novel drug classes to treat diabetes, such as dual-action drugs that target multiple pathways in the body, presents a significant opportunity. As patients and healthcare providers seek more effective treatments with fewer side effects, pharmaceutical companies have the chance to introduce innovative drugs that can transform the way diabetes is managed. Research into drugs that not only control blood sugar but also improve cardiovascular health and weight management is gaining traction.
- Diabetes Drugs for Pediatric Populations: Because the number of children and adolescents with newly diagnosed cases of Type 1 and Type 2 diabetes is on the rise, companies manufacturing drugs have a huge and growing opportunity. There is an urgent demand for drugs that specifically treat children; they must be safe, effective, and easy to administer. As more children are diagnosed with diabetes, pharmaceutical companies have a chance to develop medications focused on the needs of pediatric patients.
- Investment in Diabetes Drug Delivery Systems: This explains investment opportunities through innovative drug delivery systems, such as insulin pumps and smart pens, together with the continuously scanned glucose monitoring system. These devices make it easier and more accurate for the patient to manage the disease while improving medication adherence. An opportunity for huge market growth can arise from partnerships between pharmaceuticals and medical device companies looking to integrate systems into solutions for diabetes care.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Diabetes Care Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Diabetes Care Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Diabetes Care Drugs Market are Increasing Prevalence of Diabetes, Advances in Drug Formulations and Therapies, and Government Initiatives and Awareness Campaigns
The key future trends of the market are Shift Towards Personalized Medicine, Rising Biosimilars Trend in Diabetes Care, and Integration of digital health technologies
The leading players operating in the Diabetes Care Drugs Market include AstraZeneca plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Sanofi S.A.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Diabetes Care Drugs Market - By Product
1.3.2 Diabetes Care Drugs Market - By Distribution Channel
1.3.3 Diabetes Care Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. DIABETES CARE DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. DIABETES CARE DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. DIABETES CARE DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. DIABETES CARE DRUGS - GLOBAL MARKET OVERVIEW
6.2. DIABETES CARE DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. DIABETES CARE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. INJECTABLE
7.3.1. Overview
7.3.2. Injectable Market Forecast and Analysis
7.3.3. Insulin Market
7.3.3.1. Overview
7.3.3.2. Insulin Market Forecast and Analysis
7.3.4. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists/Incretin Mimetics Market
7.3.4.1. Overview
7.3.4.2. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists/Incretin Mimetics Market Forecast and Analysis
7.3.5. Amylin Analogue/Amylinomimetic Drugs Market
7.3.5.1. Overview
7.3.5.2. Amylin Analogue/Amylinomimetic Drugs Market Forecast and Analysis
7.4. ORAL ANTIDIABETIC DRUGS
7.4.1. Overview
7.4.2. Oral Antidiabetic Drugs Market Forecast and Analysis
7.4.3. Biguanides Market
7.4.3.1. Overview
7.4.3.2. Biguanides Market Forecast and Analysis
7.4.4. Sulfonylureas Market
7.4.4.1. Overview
7.4.4.2. Sulfonylureas Market Forecast and Analysis
7.4.5. Thiazolidinediones Market
7.4.5.1. Overview
7.4.5.2. Thiazolidinediones Market Forecast and Analysis
7.4.6. Alpha-Glucosidase Inhibitors Market
7.4.6.1. Overview
7.4.6.2. Alpha-Glucosidase Inhibitors Market Forecast and Analysis
7.4.7. Dipeptidyl Peptidase Iv (Dpp-4) Inhibitors/Gliptins Market
7.4.7.1. Overview
7.4.7.2. Dipeptidyl Peptidase Iv (Dpp-4) Inhibitors/Gliptins Market Forecast and Analysis
7.4.8. Meglitinides Market
7.4.8.1. Overview
7.4.8.2. Meglitinides Market Forecast and Analysis
7.4.9. Sodium-Glucose Cotransporter-2 (Sglt2) Inhibitors/Gliflozins Market
7.4.9.1. Overview
7.4.9.2. Sodium-Glucose Cotransporter-2 (Sglt2) Inhibitors/Gliflozins Market Forecast and Analysis
8. DIABETES CARE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. ONLINE PHARMACIES
8.3.1. Overview
8.3.2. Online Pharmacies Market Forecast and Analysis
8.4. HOSPITAL PHARMACIES
8.4.1. Overview
8.4.2. Hospital Pharmacies Market Forecast and Analysis
8.5. RETAIL PHARMACIES
8.5.1. Overview
8.5.2. Retail Pharmacies Market Forecast and Analysis
9. DIABETES CARE DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Diabetes Care Drugs Market Overview
9.1.2 North America Diabetes Care Drugs Market Forecasts and Analysis
9.1.3 North America Diabetes Care Drugs Market Forecasts and Analysis - By Product
9.1.4 North America Diabetes Care Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Diabetes Care Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Diabetes Care Drugs Market
9.1.5.1.1 United States Diabetes Care Drugs Market by Product
9.1.5.1.2 United States Diabetes Care Drugs Market by Distribution Channel
9.1.5.2 Canada Diabetes Care Drugs Market
9.1.5.2.1 Canada Diabetes Care Drugs Market by Product
9.1.5.2.2 Canada Diabetes Care Drugs Market by Distribution Channel
9.1.5.3 Mexico Diabetes Care Drugs Market
9.1.5.3.1 Mexico Diabetes Care Drugs Market by Product
9.1.5.3.2 Mexico Diabetes Care Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Diabetes Care Drugs Market Overview
9.2.2 Europe Diabetes Care Drugs Market Forecasts and Analysis
9.2.3 Europe Diabetes Care Drugs Market Forecasts and Analysis - By Product
9.2.4 Europe Diabetes Care Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Diabetes Care Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Diabetes Care Drugs Market
9.2.5.1.1 Germany Diabetes Care Drugs Market by Product
9.2.5.1.2 Germany Diabetes Care Drugs Market by Distribution Channel
9.2.5.2 France Diabetes Care Drugs Market
9.2.5.2.1 France Diabetes Care Drugs Market by Product
9.2.5.2.2 France Diabetes Care Drugs Market by Distribution Channel
9.2.5.3 Italy Diabetes Care Drugs Market
9.2.5.3.1 Italy Diabetes Care Drugs Market by Product
9.2.5.3.2 Italy Diabetes Care Drugs Market by Distribution Channel
9.2.5.4 Spain Diabetes Care Drugs Market
9.2.5.4.1 Spain Diabetes Care Drugs Market by Product
9.2.5.4.2 Spain Diabetes Care Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Diabetes Care Drugs Market
9.2.5.5.1 United Kingdom Diabetes Care Drugs Market by Product
9.2.5.5.2 United Kingdom Diabetes Care Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Diabetes Care Drugs Market Overview
9.3.2 Asia-Pacific Diabetes Care Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Diabetes Care Drugs Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Diabetes Care Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Diabetes Care Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Diabetes Care Drugs Market
9.3.5.1.1 Australia Diabetes Care Drugs Market by Product
9.3.5.1.2 Australia Diabetes Care Drugs Market by Distribution Channel
9.3.5.2 China Diabetes Care Drugs Market
9.3.5.2.1 China Diabetes Care Drugs Market by Product
9.3.5.2.2 China Diabetes Care Drugs Market by Distribution Channel
9.3.5.3 India Diabetes Care Drugs Market
9.3.5.3.1 India Diabetes Care Drugs Market by Product
9.3.5.3.2 India Diabetes Care Drugs Market by Distribution Channel
9.3.5.4 Japan Diabetes Care Drugs Market
9.3.5.4.1 Japan Diabetes Care Drugs Market by Product
9.3.5.4.2 Japan Diabetes Care Drugs Market by Distribution Channel
9.3.5.5 South Korea Diabetes Care Drugs Market
9.3.5.5.1 South Korea Diabetes Care Drugs Market by Product
9.3.5.5.2 South Korea Diabetes Care Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Diabetes Care Drugs Market Overview
9.4.2 Middle East and Africa Diabetes Care Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Diabetes Care Drugs Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Diabetes Care Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Diabetes Care Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Diabetes Care Drugs Market
9.4.5.1.1 South Africa Diabetes Care Drugs Market by Product
9.4.5.1.2 South Africa Diabetes Care Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Diabetes Care Drugs Market
9.4.5.2.1 Saudi Arabia Diabetes Care Drugs Market by Product
9.4.5.2.2 Saudi Arabia Diabetes Care Drugs Market by Distribution Channel
9.4.5.3 U.A.E Diabetes Care Drugs Market
9.4.5.3.1 U.A.E Diabetes Care Drugs Market by Product
9.4.5.3.2 U.A.E Diabetes Care Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Diabetes Care Drugs Market Overview
9.5.2 South and Central America Diabetes Care Drugs Market Forecasts and Analysis
9.5.3 South and Central America Diabetes Care Drugs Market Forecasts and Analysis - By Product
9.5.4 South and Central America Diabetes Care Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Diabetes Care Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Diabetes Care Drugs Market
9.5.5.1.1 Brazil Diabetes Care Drugs Market by Product
9.5.5.1.2 Brazil Diabetes Care Drugs Market by Distribution Channel
9.5.5.2 Argentina Diabetes Care Drugs Market
9.5.5.2.1 Argentina Diabetes Care Drugs Market by Product
9.5.5.2.2 Argentina Diabetes Care Drugs Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. DIABETES CARE DRUGS MARKET, KEY COMPANY PROFILES
11.1. ASTRAZENECA PLC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BOEHRINGER INGELHEIM GMBH
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ELI LILLY AND COMPANY
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GLAXOSMITHKLINE PLC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. JOHNSON AND JOHNSON
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. MERCK AND CO., INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. NOVARTIS AG
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. NOVO NORDISK
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SANOFI S.A.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. AstraZeneca plc.
2. Boehringer Ingelheim GmbH
3. Eli Lilly and Company
4. GlaxoSmithKline plc.
5. Johnson & Johnson
6. Merck & Co., Inc.
7. Novartis AG
8. Novo Nordisk
9. Sanofi S.A.
10. Takeda Pharmaceutical Company Limited
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For